Comparing the current results to its competitors, Alpine Immune Sciences Inc reported Revenue decrease in the 1 quarter 2024 year on year by -25.09 %, despite the revenue increase by the most of its competitors of 30.75 %, recorded in the same quarter.
Alpine Immune Sciences Inc , slower than the average decrease reported by the company's competitors of -92.38 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -92.38 %
Alpine Immune Sciences Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and both public and private research organizations. Competitors may achieve FDA or other regulatory approvals more quickly, potentially securing market positions before the company enters. Many competitors possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory processes, and marketing. Smaller or early-stage companies can also be significant competitors, particularly through partnerships with larger firms. Competition extends to recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. Notably, competitors include companies developing therapies targeting the same mechanisms as acazicolcept and povetacicept.
March 21, 2024
Alpine Immune Sciences Presents Promising Translational Data on Povetacicept and Acazicolcept for the Treatment of Lupus and Glomerulonephritis Alpine Immune Sciences, a leading clinical-stage immunotherapy company, recently presented new translational data on two of their innovative treatments for autoimmune and inflammatory diseases at prestigious medical conferences. The presentations shed light on the potential of povetacicept (ALPN-303) and acazicolcept (ALPN-101) in the treatment of systemic lupus erythematosus (SLE) and autoimmune glomerulonephritis.At the SLEuro 14th European Lupus Meeting in Bruges, Belgium, Alpine Immune Sciences unveiled compelling translational data on povetacicept. The data demo...
December 21, 2023
Alpine Immune Sciences Updates License Agreement with AbbVie and Demonstrates Revenue GrowthSeattle-based immunotherapy company, Alpine Immune Sciences, has announced an amendment to its option and license agreement with AbbVie, a global biopharmaceutical company. The agreement focuses on the development of acazicolcept, an innovative treatment for autoimmune and inflammatory diseases. The amendment includes halting enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus. Under the terms of the amended agreement, Alpine Immune Sciences will be able to further strengthen its partnership with AbbVie, allowing both companies to collaboratively explore new opportunities in immunotherapy. ...
Publicly Traded Peers of Alpine Immune Sciences Inc
Medicinova Inc Share Performance
+6.57%
This Quarter
Medicinova Inc
Profile
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Prometheus Biosciences Inc is a biotechnology company that operates on a subscription-based business model. Their platform offers personalized diagnostic tools and services to healthcare providers, enabling them to deliver targeted treatments for patients with gastrointestinal diseases. By providing ongoing support and monitoring, Prometheus aims to improve patient outcomes and revolutionize the management of chronic conditions in the field of gastroenterology.
Structure Therapeutics Inc is a biotechnology company that utilizes a structure-based approach to develop innovative therapeutics. They focus on identifying and targeting unique protein structures to create novel drugs for various diseases.
Sources:
Alpine Immune Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alpine Immune Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
